MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis.

In conclusion, our integrated approach demonstrated that decreased expression of lncRNA MEG3 in CRC confers potent poor therapeutic efficacy, and that MEG3 promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis. Thus, overexpression of MEG3 may be a future direction by which to develop a novel therapeutic strategy to overcome oxaliplatin resistance of CRC patients. PMID: 28731151 [PubMed - as supplied by publisher] (Source: Oncology Reports)

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2vLXzFI
via IFTTT